Iranian Journal of Allergy, Asthma and Immunology 2017. 16(4):289-297.

Peptide-based Vaccines Derived from FcεRI Beta Subunit Can Reduce Allergic Response in Mice Model
Ahad Zare, Ali Akbar Pourfathollah, Zahra Pourpak, Janos Szebeni, Seyed Mohammad Reza Ghaffari, Gholam Ali Kardar


Current therapeutic approaches in allergic diseases especially asthma generally focus on using immunological strategies. According to the importance of FceRI in controlling allergic response we used two extracellular regions of Fc epsilon receptor I (FceRI) beta subunit peptides to design two peptide-based vaccines. Probably these peptides vaccines by triggering the immune response to FceRI can reduce the allergic symptoms through blocking the IgE specific receptor. Two extracellular parts of FceRI beta subunit were made by peptide synthesizer and conjugated with keyhole limpet Hemocyanin. These conjugated peptides were used and evaluated as therapeutic vaccines in allergic airway inflammation mouse model. Total IgE and anti ovalbumin specific IgE were measured in mice serum and compared in vaccinated and unvaccinated allergic mice. Histamine, prostaglandin D2 (PGD2), IL-4 and IL-13 were measured in bronchoalveolar lavage (BAL) fluid of vaccinated allergic mice versus unvaccinated and histopathologic examination were performed in studied groups. After vaccination of mice with each of the peptide vaccines the specific antibodies titer increased significantly in vaccinated groups versus unvaccinated. In histopathologic study, lavage eosinophil percentage and peribronchial inflammation in lung sections of vaccinated groups was decreased (p<0.05). Also the allergic components including total IgE, anti ovalbumin specific IgE, histamine, PGD2, IL-4, and IL-13 showed substantial decline in vaccinated allergic mice.  Thus targeting the extracellular regions of FceRI beta subunit by peptide-based vaccines and induction of specific antibodies against them can reduce allergic responses in allergic mice model.  


Allergy; FcεRI beta-subunit; Peptide-based vaccine

Full Text:



Weinberg EG. The Wao White Book on Allergy 2011-2012. Curr Allergy Clin Im 2011; 24(3):156-7.

2. Sicherer SH, Leung DY. Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2012. J Allergy Clin Immunol 2013; 131(1):55-66.

3. Pawankar R. Allergic diseases and asthma: a global public health concern and a call to action. World Allergy Organ J 2014; 7(1):12.

4. Holgate ST, Polosa R. Treatment strategies for allergy and asthma. Nat Rev Immunol 2008; 8(3):218-30.

5. Vernersson M, Ledin A, Johansson J, Hellman L. Generation of therapeutic antibody responses against IgE through vaccination. Faseb J 2002; 16(8):875-7.

6. Ballantyne SJ, Barlow JL, Jolin HE, Nath P, Williams AS, Chung KF, et al. Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma. J Allergy Clin Immunol 2007; 120(6):1324-31.

7. Zagury D, Le Buanec H, Bizzini B, Burny A, Lewis G, Gallo RC. Active versus passive anti-cytokine antibody therapy against cytokine-associated chronic diseases. Cytokine and growth factor reviews 2003; 14(2):123-37.

8. Nechansky A, Robertson MW, Albrecht BA, Apgar JR, Kricek F. Inhibition of antigen-induced mediator release from IgE-sensitized cells by a monoclonal anti-Fc epsilon RI alpha-chain receptor antibody: implications for the involvement of the membrane-proximal alpha-chain region in Fc epsilon RI-mediated cell activation. J Immunol 2001; 166(10):5979-90.

9. Takai T, Yuuki T, Ra C. Inhibition of IgE-dependent histamine release from human peripheral blood basophils by humanized Fab fragments that recognize the membrane proximal domain of the human Fc epsilon RI alpha-chain. Int Arch Allergy Immunol 2000; 123(4):308-18.

10.Kricek F, Ruf C, Rudolf MP, Effenberger F, Mayer P, Stadler BM. IgE-related peptide mimotopes. Basic structures for anti-allergy vaccine development. Int Arch Allergy Immunol 1999; 118(2-4):222-3.

11.Ma Y, HayGlass KT, Becker AB, Fan Y, Yang X, Basu S, et al. Novel recombinant interleukin-13 peptide-based vaccine reduces airway allergic inflammatory responses in mice. Am J Respir Crit Care Med 2007; 176(5):439-45.

12.Peng Z, Liu Q, Wang Q, Rector E, Ma Y, Warrington R. Novel IgE peptide-based vaccine prevents the increase of IgE and down-regulates elevated IgE in rodents. Clin Exp Allergy 2007; 37(7):1040-8.

13.Wang CY, Walfield AM, Fang X, Hammerberg B, Ye J, Li ML, et al. Synthetic IgE peptide vaccine for immunotherapy of allergy. Vaccine 2003; 21(15):1580-90.

14.Focke-Tejkl M, Valenta R. Safety of engineered allergen-specific immunotherapy vaccines. Curr Opin Allergy Clin Immunol 2012; 12(5):555-63.

15.Kleine-Tebbe J, Ackermann-Simon J, Hanf G. [Role of allergen-specific immunotherapy (desensitization) for the treatment of allergies in Germany. Current situation]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2012; 55(3):343-50.

16.Chan JH, Liao W, Lau HY, Wong WS. Gab2 antisense oligonucleotide blocks rat basophilic leukemic cell functions. Int Immunopharmacol 2007; 7(7):937-44.

17.Safaralizadeh R, Soheili ZS, Deezagi A, Pourpak Z, Samiei S, Moin M. FcepsilonRI-alpha siRNA Inhibits the Antigen-Induced Activation of Mast Cells. Iran J Allergy Asthma Immunol 2009; 8(4):177-83.

18.Qian W, Zhang X, Li B, Zhang D, Tong Q, Chen L, et al. Development and characterization of a novel anti-IgE monoclonal antibody. Biochem Biophys Res Commun 2010; 395(4):547-52.

19.Peng Z. Vaccines targeting IgE in the treatment of asthma and allergy. Hum vaccines 2009; 5(5):302-9.

20.Sabroe RA, Poon E, Orchard GE, Lane D, Francis DM, Barr RM, et al. Cutaneous inflammatory cell infiltrate in chronic idiopathic urticaria: comparison of patients with and without anti-FcepsilonRI or anti-IgE autoantibodies. J Allergy Clin Immunol 1999; 103(3 Pt 1):484-93.

21.Sabroe RA, Fiebiger E, Francis DM, Maurer D, Seed PT, Grattan CE, et al. Classification of anti-FcepsilonRI and anti-IgE autoantibodies in chronic idiopathic urticaria and correlation with disease severity. J Allergy Clin Immunol. 2002; 110(3):492-9.

22.Goh CL, Tan KT. Chronic autoimmune urticaria: where we stand? Indian J Dermatol 2009; 54(3):269-74.

23.Rector E, Nakajima T, Rocha C, Duncan D, Lestourgeon D, Mitchell RS, et al. Detection and characterization of monoclonal antibodies specific to IgE receptors on human lymphocytes by flow cytometry. Immunology 1985; 55(3):481-8.

24.Erdei A, Toth GK, Andrasfalvy M, Matko J, Bene L, Bajtay Z, et al. Inhibition of IgE-mediated triggering of mast cells by complement-derived peptides interacting with the Fc epsilon RI. Immunol Lett 1999; 68(1):79-82.

25.Erdei A, Andreev S, Pecht I. Complement peptide C3a inhibits IgE-mediated triggering of rat mucosal mast cells. Int Immunol 1995; 7(9):1433-9.

26.Erdei A, Andrasfalvy M, Peterfy H, Toth G, Pecht I. Regulation of mast cell activation by complement-derived peptides. Immunol Lett 2004; 92(1-2):39-42.

27.Zare A, Farzaneh P, Pourpak Z, Zahedi F, Moin M, Shahabi S, et al. Purified aged garlic extract modulates allergic airway inflammation in BALB/c mice. Iran J Allergy Asthma Immunol 2008; 7(3):133-41.

28.Kadkhoda K, Pourfathollah AA, Pourpak Z, Kazemnejad A. The cumulative activity of benzo(a)pyrene on systemic immune responses with mite allergen extract after intranasal instillation and ex vivo response to ovalbumin in mice. Toxicol Lett 2005; 157(1):31-9.

29.Farzaneh P, Hassan ZM, Pourpak Z, Hoseini AZ, Hogan SP. A latex-induced allergic airway inflammation model in mice. Basic Clin Pharmacol Toxicol 2006; 99(6):405-11.

30.Velumani S, Ho HT, He F, Musthaq S, Prabakaran M, Kwang J. A novel peptide ELISA for universal detection of antibodies to human H5N1 influenza viruses. PloS one 2011; 6(6):e20737.

31. David C. Hancock and Nicola J. O’Reilly, Synthetic Peptides as Antigens for Antibody Production, Methods in Molecular Biology, Immunochemical Protocols 2005;295.

32.Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature 2008; 454(7203):445-54.


  • There are currently no refbacks.

Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.